Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS3 | P17931 | 6/20 | 0.62 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.62 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.62 |
| ▸ | CD69 | Q07108 | 1/20 | 0.57 |
| ▸ | CHIA | Q9BZP6 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | THRB | P10828 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.53 |
| ▸ | LGALS1 | P09382 | 1/20 | 0.50 |
| ▸ | LGALS7; LGALS7B | P47929 | 1/20 | 0.50 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.48 |
| ▸ | AMY2A | P04746 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29533372 | 0.96 | LGALS3 (0.67) | LGALS3LGALS8LGALS4CD69CHIA | |
| SCHEMBL29466465 | 0.96 | LGALS3 (0.67) | LGALS3LGALS8LGALS4CD69CHIA | |
| Chitodextrin SCHEMBL619917 | 0.96 | CD69 (0.60) | LGALS3LGALS8LGALS4CD69CHIA | |
| Chitodextrin SCHEMBL19427436 | 0.96 | CD69 (0.60) | LGALS3LGALS8LGALS4CD69CHIA | |
| N-Acetylchitopentaose SCHEMBL20390680 | 0.96 | CD69 (0.60) | LGALS3LGALS8LGALS4CD69CHIA | |
| Triacetylchitotriose SCHEMBL974524 | 0.96 | CD69 (0.60) | LGALS3LGALS8LGALS4CD69CHIA | |
| Chitodextrin SCHEMBL13046690 | 0.96 | CD69 (0.60) | LGALS3LGALS8LGALS4CD69CHIA | |
| Chitodextrin SCHEMBL619918 | 0.96 | CD69 (0.60) | LGALS3LGALS8LGALS4CD69CHIA | |
| Chitodextrin SCHEMBL21067311 | 0.96 | CD69 (0.60) | LGALS3LGALS8LGALS4CD69CHIA | |
| Triacetylchitotriose SCHEMBL425647 | 0.96 | CD69 (0.60) | LGALS3LGALS8LGALS4CD69CHIA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260114433-A1 | HUMANIZATION OF BETA2-MICROGLOBULIN IN PORCINE GENOME RESULTING IN FUNCTIONAL EXPRESSION OF HUMAN BETA2-MICROGLOBULIN WITHIN DONOR CELLS, TISSUES, OR ORGANS | XENOTHERAPEUTICS, INC. (US) | 2026-04-30 | — | — | US | disclosed |
| US-20220053739-A1 | IMMUNOLOGICALLY COMPATIBLE CELLS, TISSUES, ORGANS, AND METHODS FOR TRANSPLANTATION FOR SILENCING, HUMANIZATION, AND PERSONALIZATION WITH MINIMIZED COLLATERAL GENOMIC DISRUPTIONS | XENOTHERAPEUTICS, INC. (US) | 2022-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260114433-A1 | HUMANIZATION OF BETA2-MICROGLOBULIN IN PORCINE GENOME RESULTING IN FUNCTIONAL EXPRESSION OF HUMAN BETA2-MICROGLOBULIN WITHIN DONOR CELLS, TISSUES, OR ORGANS | B2M, PIGS, IL2RA | LGALS3 1086/4885LGALS8 1025/4885LGALS4 461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.